RRC ID 65456
著者 Ando H, Emam SE, Kawaguchi Y, Shimizu T, Ishima Y, Eshima K, Ishida T.
タイトル Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes.
ジャーナル Biol Pharm Bull
Abstract Acidic extracellular pH (pHe) is characteristic of the tumor microenvironment. Several reports suggest that increasing pHe improves the response of immune checkpoint inhibitors in murine models. To increase pHe, either sodium bicarbonate (NaHCO3) or citric acid/potassium-sodium citrate (KNa-cit) was chronically administered to mice. It is hypothesized that bicarbonate ions (HCO3-), produced from these alkalinizing agents in vivo, increased pHe in the tumor, and excess HCO3- eliminated into urine increased urinary pH values. However, there is little published information on the effect of changing serum HCO3- concentrations, urinary HCO3- concentrations and urinary pH values on the therapeutic outcomes of immunotherapy. In this study, we report that oral administration of either NaHCO3 or KNa-cit increased responses to anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor, in a murine B16 melanoma model. In addition, we report that daily oral administration of an alkalinizing agent increased blood HCO3- concentrations, corresponding to increasing the tumor pHe. Serum HCO3- concentrations also correlated with urinary HCO3- concentrations and urinary pH values. There was a clear relationship between urinary pH values and the antitumor effects of immunotherapy with anti-PD-1 antibody. Our results imply that blood HCO3- concentrations, corresponding to tumor pHe and urinary pH values, may be important factors that predict the clinical outcomes of an immunotherapeutic agent, when combined with alkalinizing agents such as NaHCO3 and KNa-cit.
巻・号 44(6)
ページ 844-852
公開日 2021-1-1
DOI 10.1248/bpb.b21-00076
PMID 34078817
MeSH Administration, Oral Animals Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal / therapeutic use* Antineoplastic Agents, Immunological / pharmacology Antineoplastic Agents, Immunological / therapeutic use* Bicarbonates / blood Bicarbonates / pharmacology Bicarbonates / therapeutic use* Cell Line, Tumor Citrates / pharmacology Citrates / therapeutic use* Female Hydrogen-Ion Concentration Immune Checkpoint Inhibitors / pharmacology Immune Checkpoint Inhibitors / therapeutic use* Lymphocytes / immunology Mice, Inbred BALB C Mice, Inbred C57BL Neoplasms / chemistry Neoplasms / drug therapy* Neoplasms / immunology Neoplasms / metabolism Programmed Cell Death 1 Receptor / antagonists & inhibitors* Ribosomal Protein S6 Kinases / metabolism Tumor-Associated Macrophages / immunology Urine / chemistry
IF 1.863
リソース情報
ヒト・動物細胞 Colon-26(RCB2657) B16/BL6(RCB2638)